Jingfang Pharmaceutical-B (02595): A number of innovative combination therapies for oral administration of the RAS inhibitor GFH276 have recently obtained clinical trial approval to carry out first-line and back-line clinical studies of large-scale indicated tumors at home or abroad

Zhitong Finance App News, Jingfang Pharmaceutical-B (02595) announced that since the third quarter of this year, several innovative combination therapies for oral administration of the broad RAS inhibitor GFH276 have obtained clinical trial licenses issued by the domestic CDE or completed the Australian TGA clinical trial registration. Relevant studies cover first-line and post-line treatment for multiple high-indication RAS mutations, and some trials have enrolled patients at multiple dose levels.